# Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

> **NCT02351037** · PHASE2 · TERMINATED · sponsor: **Pharmacyclics LLC.** · enrollment: 36 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Ibrutinib + LD-AraC
- **DRUG:** Ibrutinib+Azacitidine

## Key facts

- **NCT ID:** NCT02351037
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Study data do not support development in AML.
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02351037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02351037, "Study of Ibrutinib in Subjects With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02351037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*